Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound 14c
- Development stage
- Preclinical
- Modality
- Small Molecules, Peptides
- Administration
- Oral
01
Overview
The identifier "compound 14c" is a non-specific code name used across numerous independent research studies to refer to a variety of distinct experimental small molecules. These compounds exhibit diverse mechanisms of action and are being investigated for a wide range of therapeutic applications, including antibacterial, antifungal, antiviral, anticancer, anti-inflammatory, antileishmanial, and neuroprotective effects, as well as for hypertension. Due to its non-specific nature, "compound 14c" does not refer to a single drug but rather to multiple unique chemical entities synthesized and evaluated in different contexts.
02
Targets
AcetylcholinesteraseCDK2 (Cyclin-dependent kinase 2)CDC20 (Cell division cycle protein 20 homolog)LdNTR1 (Leishmania donovani nitroreductase 1)TOP2A (DNA topoisomerase II)TGFBR1CYP19A1 (Aromatase)BRAF (B-Raf proto-oncogene, serine/threonine kinase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)MAPK3 (Mitogen-activated protein kinase 1)HDAC4MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)NKG2D (Natural killer group 2 member D receptor)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NOS2 (Nitric Oxide Synthase 2)PDE2 (Phosphodiesterase 2)PDE5 (Phosphodiesterase 5A)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)PTC (50S ribosomal peptidyl transferase center)TERT (Telomerase)telomeric G4 (Telomeric DNA G-quadruplex)TXNRD2 (Thioredoxin reductase 2)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)JNK (Mitogen-activated protein kinase kinase kinase family)
Beyond the preview
Go deeper on compound 14c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound 14c.